McAdam LLC Invests $206,000 in Agilent Technologies Inc (A) Stock

McAdam LLC bought a new stake in Agilent Technologies Inc (NYSE:A) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,559 shares of the medical research company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Captrust Financial Advisors boosted its position in Agilent Technologies by 2,121.1% in the fourth quarter. Captrust Financial Advisors now owns 422 shares of the medical research company’s stock valued at $29,000 after buying an additional 403 shares during the last quarter. Lake Point Wealth Management purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $30,000. JOYN Advisors Inc. boosted its position in Agilent Technologies by 186.6% in the 4th quarter. JOYN Advisors Inc. now owns 470 shares of the medical research company’s stock worth $32,000 after purchasing an additional 306 shares in the last quarter. Truehand Inc purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $33,000. Finally, We Are One Seven LLC purchased a new stake in Agilent Technologies in the 4th quarter worth approximately $33,000.

In related news, Director Paul N. Clark sold 2,823 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $80.31, for a total value of $226,715.13. Following the completion of the transaction, the director now directly owns 88,857 shares of the company’s stock, valued at approximately $7,136,105.67. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 17,491 shares of the stock in a transaction on Wednesday, January 30th. The shares were sold at an average price of $75.00, for a total value of $1,311,825.00. Following the completion of the transaction, the chief executive officer now directly owns 456,430 shares of the company’s stock, valued at $34,232,250. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,722 shares of company stock valued at $6,532,504.

Shares of A stock traded down $0.97 during trading hours on Monday, hitting $75.20. 93,931 shares of the company’s stock were exchanged, compared to its average volume of 1,737,020. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.39 and a quick ratio of 2.79. The company has a market cap of $24.19 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 2.12 and a beta of 1.38. Agilent Technologies Inc has a fifty-two week low of $60.42 and a fifty-two week high of $82.27.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 20th. The medical research company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a return on equity of 19.90% and a net margin of 22.86%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.66 EPS. Analysts anticipate that Agilent Technologies Inc will post 3.06 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be paid a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s payout ratio is 23.66%.

A has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and issued a $88.00 price objective (up previously from $77.00) on shares of Agilent Technologies in a research report on Monday, February 25th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a research report on Friday, February 22nd. Janney Montgomery Scott restated a “buy” rating and issued a $90.00 price objective (up previously from $80.00) on shares of Agilent Technologies in a research report on Thursday, February 21st. Bank of America restated a “buy” rating and issued a $87.00 price objective (up previously from $78.00) on shares of Agilent Technologies in a research report on Thursday, February 21st. Finally, Deutsche Bank restated a “buy” rating and issued a $90.00 price objective on shares of Agilent Technologies in a research report on Thursday, February 21st. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $87.17.

COPYRIGHT VIOLATION WARNING: “McAdam LLC Invests $206,000 in Agilent Technologies Inc (A) Stock” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/22/mcadam-llc-invests-206000-in-agilent-technologies-inc-a-stock.html.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

See Also: FAANG Stocks

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.